The Von Hippel-Lindau (VHL) gene product has a wide spectrum of tissue-specific functions, and specific germline mutations are associated with clinical phenotypes in VHL disease. In particular, missense mutations are correlated with the susceptibility to pheochromocytomas. An association between VHL aberrations and prognosis has been suggested in renal clear cell carcinoma but has not been studied in pheochromocytomas. We studied the frequency and spectrum of VHL alterations in apparently sporadic pheochromocytomas in relation to the clinical behavior in 72 patients, including 48 patients with clinically benign and 24 patients with malignant pheochromocytomas. Single-strand conformation polymorphism (SSCP) analysis followed by DNA sequencing, loss of heterozygosity analysis of the VHL locus and immunohistochemistry for VHL protein expression were used to investigate somatic VHL gene alterations. In 2 patients, 1 with a malignant tumor, germline mutations were identified in the stop codon. Tumor-specific intragenic VHL mutations and accompanying loss of heterozygosity were identified in 2 (4.3%) of 47 sporadic benign pheochromocyto-
Key words: Von Hippel-Lindau; pheochromocytoma; mutation; loss of heterozygosityVon Hippel-Lindau (VHL) disease is characterized by the development of multiple highly vascularized tumors in mesenchymal and neural crest-derived tissues of several organ systems. These concern mostly the central nervous system (hemangioblastoma), eye (retinal angioma), kidney (renal clear cell carcinoma), adrenal medulla (pheochromocytoma), inner ear (endolymphatic sac tumor) and endocrine pancreas (islet cell tumors). 1 In nearly all VHL patients, germline mutations or deletions in the VHL gene can be identified. 2,3 The VHL gene codes for a 213-amino acid protein (pVHL), which is involved in regulation of angiogenesis, extracellular matrix formation and plays a role in the cell cycle. 4 -9 As a recessive tumor suppressor gene, VHL demonstrates some important additional features, such as allelic heterogeneity resulting in genotypephenotype correlations and epigenetic effects. 10 -12 A correlation has been found between the nature and localization of inactivating mutations and the clinical consequences in patients afflicted by VHL disease. In particular, the development of pheochromocytoma (PCC) in VHL disease (type II VHL disease) is strongly correlated with missense mutations. These are found in 96% of these families, frequently in the exon 3-encoded ␣-domain of pVHL. 10 -13 PCC may even be the only tumor arising in some individuals with VHL type II disease. It is hypothesized that some retention of pVHL function is necessary in the development of PCC, arising from a dominant-negative effect of mutated pVHL and based on its involvement in the VHL-Elongin C-Elongin B complex. 14 The majority of PCCs occur sporadically, and the genetic mechanisms underlying their tumorigenesis and progression towards malignancy are poorly understood. At present, one cannot predict which patient will experience progres...